Last updated: September 25, 2026
Vanda Pharmaceuticals’ lawsuit against Teva concerned generic versions of Fanapt (iloperidone), an atypical antipsychotic approved for schizophrenia. Vanda asserted U.S. Patent Nos. 8,586,610 and 9,730,884, which cover pharmacogenetic dosing methods based on a patient’s CYP2D6 metabolizer status. The District of Delaware ultimately held the asserted claims invalid as obvious. The Federal Circuit affirmed, eliminating the principal patent barrier to Teva’s ANDA product. [1][2]
What drug and patents were at issue in Vanda v. Teva?
The case involved iloperidone, marketed by Vanda as Fanapt. The FDA approved Fanapt in 2009 for the treatment of schizophrenia in adults. The patents did not broadly claim iloperidone as a chemical compound. They claimed methods for selecting and adjusting the dose based on CYP2D6 metabolism.
| Item |
Details |
| Branded drug |
Fanapt |
| Active ingredient |
Iloperidone |
| Brand company |
Vanda Pharmaceuticals Inc. |
| Generic defendant |
Teva Pharmaceuticals USA, Inc. |
| Regulatory pathway |
Abbreviated New Drug Application, or ANDA |
| Indication |
Schizophrenia |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:18-cv-00651-CFC |
| Asserted patents |
U.S. Patent Nos. 8,586,610 and 9,730,884 |
| Patent subject matter |
CYP2D6-guided dosing of iloperidone |
| Final appellate result |
Invalidity judgment affirmed |
The asserted claims addressed patients who were poor metabolizers of CYP2D6 and patients who were not poor metabolizers. The claimed dosing strategy sought to reduce exposure-related adverse effects, including QT interval prolongation, while maintaining antipsychotic efficacy.
What patents protected Fanapt in the Vanda litigation?
U.S. Patent No. 8,586,610
The '610 patent covered methods of treating schizophrenia by administering iloperidone at specified doses according to the patient’s CYP2D6 metabolizer status. The patent was central to earlier Vanda litigation involving iloperidone and was also asserted against Teva.
The patent’s commercial significance came from its relationship to the Fanapt prescribing information. Generic applicants seeking approval for iloperidone products had to address the dosing and pharmacogenetic information associated with the patent.
U.S. Patent No. 9,730,884
The '884 patent was a later patent directed to related CYP2D6-based dosing methods. Vanda asserted claims covering administration of iloperidone to patients identified as poor metabolizers and administration of different doses to other metabolizer groups.
The two patents addressed overlapping commercial subject matter, but they were separately analyzed for validity. The litigation therefore created two independent patent obstacles for Teva’s ANDA.
| Patent |
General subject matter |
Commercial role |
| 8,586,610 |
CYP2D6-guided iloperidone dosing for schizophrenia |
Core Fanapt method-of-use patent |
| 9,730,884 |
Related dosing methods based on CYP2D6 status |
Later method-of-use protection |
The patents were method-of-use patents rather than composition-of-matter patents. Their value depended on whether the patented dosing instructions could prevent approval or commercial sale of a generic iloperidone product.
When does Fanapt lose patent exclusivity?
The asserted Fanapt patents were scheduled to expire in the 2020s, with the relevant patent term extending to approximately 2027. The litigation outcome became commercially important because the patents were the principal remaining barriers to Teva’s proposed generic launch.
The FDA’s small-molecule exclusivity for Fanapt had expired well before the Vanda-Teva litigation. FDA regulatory exclusivity and patent exclusivity were therefore separate issues:
| Exclusivity category |
Status |
| New-drug exclusivity |
Expired |
| Patent protection |
Subject to Vanda-Teva litigation |
| Regulatory pathway |
ANDA approval |
| Biosimilar exclusivity |
Not applicable |
| Principal legal risk |
Patent invalidity, infringement and launch timing |
A patent expiration date does not by itself determine the earliest generic launch date. Paragraph IV litigation, a 30-month stay, court-ordered relief and any settlement terms can affect launch timing. Here, the invalidity judgment removed the asserted patents as a basis for blocking Teva’s product.
What was the legal basis for Vanda’s lawsuit against Teva?
Vanda filed the action after Teva submitted an ANDA seeking approval for generic iloperidone tablets. Teva’s ANDA included a Paragraph IV certification asserting that the relevant Vanda patents were invalid, unenforceable or would not be infringed.
Vanda responded by asserting patent infringement under the Hatch-Waxman Act. The filing of the action triggered the statutory 30-month stay of FDA approval, subject to earlier termination or court action. The case was litigated as an ANDA patent dispute rather than as a conventional damages action based on commercial generic sales.
The central issues were:
- Whether Teva’s proposed product and labeling would practice the claimed dosing methods.
- Whether the asserted claims were invalid as obvious under 35 U.S.C. § 103.
- Whether the prior art provided a reason to use CYP2D6 testing and the claimed dose adjustments.
- Whether a skilled artisan would have had a reasonable expectation of success.
- Whether the claims were adequately supported by the written description and specification.
What did the District of Delaware decide?
The District of Delaware held the asserted claims invalid as obvious. The court’s analysis focused on the combination of prior-art information concerning iloperidone, CYP2D6 metabolism, dose exposure and QT prolongation.
The court rejected Vanda’s position that the claimed dosing methods represented a nonobvious clinical discovery. The decision treated the prior art as providing sufficient motivation to investigate CYP2D6-dependent dosing and sufficient reason to expect that dose reduction for poor metabolizers would reduce exposure-related safety risks.
The court also considered Vanda’s arguments that the prior art did not provide a reliable prediction of clinical outcomes. The court concluded that the obviousness standard did not require certainty. A reasonable expectation of success was sufficient.
The invalidity ruling meant that Vanda could not obtain a lasting injunction based on the asserted claims. Because the patents were found invalid, the court did not need to impose a launch prohibition through the asserted patents.
How did the Federal Circuit rule in Vanda v. Teva?
The Federal Circuit affirmed the invalidity judgment. The appellate court agreed that the asserted claims were obvious in view of the prior art and the evidence presented at trial. [2]
The appellate analysis addressed the familiar dispute between:
- A prior-art record that identified CYP2D6 metabolism as relevant to iloperidone exposure; and
- Vanda’s argument that the prior art did not predict the precise dose adjustments or clinical results claimed in the patents.
The Federal Circuit held that the district court properly evaluated motivation to combine, reasonable expectation of success and objective indicia of nonobviousness. The court did not require the prior art to disclose every limitation in a single reference. It evaluated the claimed methods as a combination of known pharmacogenetic concepts and known iloperidone dosing information.
The decision is significant for method-of-treatment patents that convert pharmacokinetic or pharmacogenetic observations into dosing instructions. A claim can be vulnerable to obviousness when the prior art already identifies:
- The drug’s metabolism pathway;
- A patient subgroup with increased exposure;
- A safety concern associated with exposure; and
- A clinically logical dose adjustment.
Did Teva infringe the Vanda patents?
Vanda’s infringement theory was based on Teva’s proposed ANDA product and labeling. In Hatch-Waxman litigation, the relevant inquiry is whether the proposed product and instructions would result in performance of the patented method after approval.
The commercial product had not yet generated ordinary market-sale damages at the time of the litigation. The case therefore centered on prospective infringement and the effect of the ANDA filing. Once the asserted claims were held invalid, infringement could not support an injunction or damages remedy under those claims.
The practical result was that Teva’s proposed generic product was no longer blocked by the two asserted patents.
Was there a Paragraph IV challenge?
Yes. Teva’s ANDA included a Paragraph IV certification directed to Vanda’s listed patents. Vanda’s subsequent infringement action created the Hatch-Waxman litigation framework and triggered the FDA approval stay.
| Hatch-Waxman issue |
Result |
| Paragraph IV certification |
Yes |
| Patent litigation filed |
Yes |
| 30-month stay |
Triggered by the infringement action |
| Trial issue |
Primarily patent validity and infringement |
| Final validity result |
Asserted claims invalid as obvious |
| Appellate result |
Invalidity affirmed |
The Paragraph IV mechanism allowed Teva to challenge the patents before commercial launch. It also gave Vanda an opportunity to delay FDA approval while litigating the patent claims.
Did Vanda and Teva settle the case?
The reported disposition was a litigated invalidity judgment followed by appellate affirmance, not a settlement-based resolution. No settlement agreement was required to remove the asserted patents as barriers after the courts held the claims invalid.
A settlement could have established a negotiated launch date, license or supply arrangement. The public litigation outcome instead produced a judicial determination against the enforceability of the asserted claims.
What was the FDA and Orange Book status of Fanapt?
Fanapt was approved through an NDA, while Teva pursued approval through an ANDA. The relevant patents were listed in the FDA’s Orange Book as patents associated with the reference product.
The Orange Book listing did not establish patent validity. It provided the regulatory basis for Teva’s patent certifications and Vanda’s Hatch-Waxman lawsuit.
| FDA issue |
Status |
| Reference product |
Fanapt |
| NDA holder |
Vanda Pharmaceuticals |
| Generic pathway |
ANDA |
| Orange Book role |
Listed patents supported Paragraph IV certifications |
| Active ingredient |
Iloperidone |
| Dosage form |
Oral tablets |
| Biologic or biosimilar pathway |
Not applicable |
Because iloperidone is a conventional small-molecule drug, the case did not involve biosimilar interchangeability, biologic patent dance procedures or FDA biologics exclusivity.
How strong was Vanda’s Fanapt patent estate?
The estate had meaningful commercial value but limited technical breadth. Its principal strength was the linkage between the patent claims and the prescribing information for Fanapt. Its principal weakness was that the patents claimed a dosing strategy built on known pharmacogenetic and pharmacokinetic relationships rather than a new iloperidone molecule.
| Strength |
Weakness |
| Patent claims tracked Fanapt dosing instructions |
Claims were method-of-use claims |
| Orange Book listing created Hatch-Waxman leverage |
No composition-of-matter protection at issue |
| CYP2D6 subgroup created a defined patient population |
Prior art addressed CYP2D6 and drug exposure |
| Patent litigation delayed generic approval |
Obviousness challenge succeeded |
| Multiple patents created overlapping protection |
Overlap did not prevent invalidity |
The Federal Circuit result materially reduced the value of the asserted Fanapt estate. It also limited Vanda’s ability to use the patents to obtain a delayed generic launch based on the same dosing concepts.
What generic launch risks existed after the judgment?
After the invalidity judgment was affirmed, the primary patent risks associated with the two asserted patents were removed. Remaining launch risks could include regulatory approval, manufacturing readiness, labeling requirements, other unasserted patents and commercial decisions by Teva.
The case did not create biosimilar risk because Fanapt is not a biologic. The competitive threat was conventional generic substitution through the ANDA pathway.
Potential commercial outcomes included:
- Teva launch after regulatory approval and resolution of the statutory stay.
- Entry by additional ANDA applicants relying on the same invalidity ruling.
- Price erosion in the iloperidone market.
- Reduced protection for Vanda’s Fanapt revenue stream.
- Increased importance of Vanda’s other products and patent estates.
Revenue exposure depends on Fanapt sales, payer substitution, the number of approved generic applicants and the timing of market entry. The litigation record does not establish a fixed damages amount because the dispute concerned prospective ANDA infringement rather than a proven period of generic sales.
How does Vanda v. Teva compare with Vanda’s earlier iloperidone litigation?
The Teva case continued Vanda’s broader effort to protect Fanapt dosing patents. Vanda had previously litigated related iloperidone claims against West-Ward Pharmaceuticals. In that earlier case, the Federal Circuit upheld the district court’s treatment of the patent claims under the applicable infringement and validity standards. [3]
The Teva outcome was less favorable because the asserted claims were ultimately held obvious. The cases illustrate that an earlier favorable result involving related claims does not immunize later claims from a new prior-art record, a different defendant’s evidence or a different trial record.
Key Takeaways
- Vanda sued Teva over an ANDA for generic iloperidone, the active ingredient in Fanapt.
- The asserted patents were U.S. Patent Nos. 8,586,610 and 9,730,884.
- The patents covered CYP2D6-guided dosing methods, not the iloperidone molecule itself.
- Teva used Paragraph IV certifications to challenge the patents.
- The District of Delaware held the asserted claims invalid as obvious.
- The Federal Circuit affirmed the invalidity judgment.
- The decision removed the principal asserted patent barriers to Teva’s generic Fanapt product.
- Biosimilar law was not relevant because Fanapt is a small-molecule drug.
- The case was resolved through litigation, not a publicly reported settlement.
- Vanda’s remaining commercial protection depended on other patents, regulatory factors and the timing of generic entry.
FAQs About Vanda Pharmaceuticals v. Teva Pharmaceuticals
What drug was involved in Vanda Pharmaceuticals v. Teva?
The case involved Fanapt, Vanda’s branded iloperidone product approved for schizophrenia.
What is the significance of U.S. Patent No. 8,586,610?
The '610 patent claimed methods for dosing iloperidone according to a patient’s CYP2D6 metabolizer status. It was one of the principal patents Vanda asserted against Teva.
Did Teva win the Vanda patent case?
Yes. Teva prevailed on invalidity, and the Federal Circuit affirmed the determination that the asserted claims were obvious.
Did the case involve Fanapt composition patents?
No. The patents at issue were method-of-treatment and pharmacogenetic dosing patents. The case did not concern a patent claiming iloperidone as a chemical compound.
Can other generic applicants rely on the Vanda v. Teva invalidity ruling?
The judgment directly binds the parties and concerns the asserted claims. Other applicants may use the reasoning and judgment in subsequent litigation, but the effect on a different applicant depends on the patents asserted, the product labeling and the applicable procedural posture.
References
- U.S. District Court for the District of Delaware. (2023). Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00651-CFC.
- U.S. Court of Appeals for the Federal Circuit. (2024). Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., appellate decision affirming invalidity of the asserted iloperidone dosing claims.
- U.S. Court of Appeals for the Federal Circuit. (2018). Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Ltd., 887 F.3d 1117.
- U.S. Food and Drug Administration. (2009). Fanapt approval package and prescribing information.
- U.S. Patent and Trademark Office. (n.d.). U.S. Patent Nos. 8,586,610 and 9,730,884.
